Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on November 29, 2019, covering events occurring on November 25, 2019. The company is incorporated in Delaware and its Class A common stock trades on the NASDAQ Capital Market under the symbol VTVT. The filing addresses a change in executive leadership.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
On November 25, 2019, Jeffrey B. Kindler resigned as Executive Chairman of the Company and terminated the Executive Chairman Agreement dated July 16, 2015. The company stated the departure was not for cause and resulted from no disagreement regarding operations, policies, or practices.
Outlook, Risks, and Management Commentary
Mr. Kindler will continue to serve as Chairman of the Board of Directors. His new compensation arrangement includes:
- An annual fee of $70,000.00, payable in quarterly installments.
- An annual option grant of 15,000 options to purchase Class A Common Stock.
The filing does not contain forward-looking guidance, risk factors, or discussion of unusual items beyond the leadership transition.
Investor Verification Checklist
- Confirm the effective date of the resignation and the termination of the prior Executive Chairman Agreement.
- Verify the specific terms of the new compensation package for the Chairman of the Board role.
- Review subsequent filings to determine if a new Executive Chairman has been appointed.
- Check the company's latest 10-Q or 10-K for financial metrics not included in this 8-K.